Capital Flow Monitor · Sponsors · CIK 2075979
Renasant Bio, Inc.
2630 BANCROFT WAY #507, BERKELEY, CA, 94704 · 650-223-5603
Biotechnology · Corporation· inc. DELAWARE true 2022
Fit score
—
Offering
$30.0M
Sold
$30.0M
% sold
100.0%
Investors
4
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-07-14 | D ·current | 506(b) | $30.0M | $30.0M | 100.0% | 4 | EDGAR ↗ |
| 2025-07-14 | D | 506(b) | $25.5M | $25.5M | 100.0% | 3 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Emily Conley — Executive Officer / Director, Berkeley, CA
- Deborah Palestrant — Director, Berkeley, CA
-
Evan Caplan — Director, Berkeley, CA
2 other raises
- Aer Therapeutics, Inc. $3.0M of $3.0M · 100.0%
- AirNexis Therapeutics, Inc. $62.0M of $200.0M · 31.0%
-
Kevin Bitterman — Director, Berkeley, CA
1 other raise
- Atlas Venture Opportunity Fund Ill, L.P. $400.0M of $400.0M · 100.0%
- Natalie Holles — Director, Berkeley, CA
-
Anna French — Director, Berkeley, CA
2 other raises
- Entact Bio, Inc. $10.0M of $10.0M · 100.0%
- Auron Therapeutics, Inc. $27.3M of $42.3M · 64.5%
- Charlotte McKee — Director, Berkeley, CA
- Thomas Gustafson — Executive Officer, Berkeley, CA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.